BRPI0821565A2 - Ingrediente farmacêutico ativo sobre um suporte sólido, amorfo e com uma solubilidade aperfeiçoada - Google Patents

Ingrediente farmacêutico ativo sobre um suporte sólido, amorfo e com uma solubilidade aperfeiçoada

Info

Publication number
BRPI0821565A2
BRPI0821565A2 BRPI0821565-0A BRPI0821565A BRPI0821565A2 BR PI0821565 A2 BRPI0821565 A2 BR PI0821565A2 BR PI0821565 A BRPI0821565 A BR PI0821565A BR PI0821565 A2 BRPI0821565 A2 BR PI0821565A2
Authority
BR
Brazil
Prior art keywords
solid
active pharmaceutical
pharmaceutical ingredient
improved solubility
amorphous support
Prior art date
Application number
BRPI0821565-0A
Other languages
English (en)
Inventor
Rock Grahek
Aleksander Resman
Andrej Bastarda
Martin Crnugelj
Original Assignee
Lek Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lek Pharmaceuticals filed Critical Lek Pharmaceuticals
Publication of BRPI0821565A2 publication Critical patent/BRPI0821565A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • A61K31/122Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0821565-0A 2007-12-21 2008-12-18 Ingrediente farmacêutico ativo sobre um suporte sólido, amorfo e com uma solubilidade aperfeiçoada BRPI0821565A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07150359A EP2072042A1 (en) 2007-12-21 2007-12-21 Active pharmaceutical ingredient on solid support, amorphous and with improved solubility
PCT/EP2008/067875 WO2009080698A1 (en) 2007-12-21 2008-12-18 Active pharmaceutical ingredient on a solid support, amorphous and with an improved solubility

Publications (1)

Publication Number Publication Date
BRPI0821565A2 true BRPI0821565A2 (pt) 2015-06-16

Family

ID=39400469

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0821565-0A BRPI0821565A2 (pt) 2007-12-21 2008-12-18 Ingrediente farmacêutico ativo sobre um suporte sólido, amorfo e com uma solubilidade aperfeiçoada

Country Status (10)

Country Link
US (1) US20100305087A1 (pt)
EP (2) EP2072042A1 (pt)
JP (1) JP2011506561A (pt)
CN (1) CN101903015A (pt)
AU (1) AU2008340057A1 (pt)
BR (1) BRPI0821565A2 (pt)
CA (1) CA2710125A1 (pt)
EA (1) EA201070780A1 (pt)
MX (1) MX2010006896A (pt)
WO (1) WO2009080698A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2238979A1 (en) * 2009-04-06 2010-10-13 LEK Pharmaceuticals d.d. Active pharmaceutical ingredient adsorbed on solid support
CN102764264A (zh) * 2012-07-25 2012-11-07 杭州和泽医药科技有限公司 一种具高溶出度的塞来昔布固体组合物、制备方法及应用
CN105102117A (zh) * 2013-02-01 2015-11-25 格雷斯公司 作为用于液体技术的载体的多孔硅胶
RU2017106094A (ru) * 2014-08-01 2018-09-04 Джонсон энд Джонсон Консьюмер Инк. Композиции ядер
CN104771761A (zh) * 2015-03-19 2015-07-15 深圳国源国药有限公司 一种创新药用辅料硅化微晶纤维素及其制备方法
DE102016218604A1 (de) 2016-09-27 2018-03-29 Constantin Adams Partikuläres Stoffgemisch, vorzugsweise zur Verwendung bei der Prophylaxe und/oder Behandlung einer Atemwegsstörung

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0129893B1 (en) 1983-06-28 1991-09-04 Takeda Chemical Industries, Ltd. Ground mixture
AU6378796A (en) * 1995-06-06 1996-12-24 Warner-Lambert Company Ranitidine salts on magnesium trisilicate as an adsorbate
WO2003000238A1 (en) * 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions of adsorbates of amorphous drug
JP2007501218A (ja) * 2003-08-04 2007-01-25 ファイザー・プロダクツ・インク 非晶質薬物の吸着物および親油性ミクロ相形成物質の医薬組成物
CA2550983C (en) * 2003-12-24 2013-09-17 Advancis Pharmaceutical Corporation Enhanced absorption of modified release dosage forms
US20070202159A1 (en) * 2006-02-02 2007-08-30 Mathur Rajeev S Pharmaceutical composition comprising stabilized statin particles
BRPI0708556A2 (pt) * 2006-03-06 2011-05-31 Teva Pharma composição de ezetimiba

Also Published As

Publication number Publication date
JP2011506561A (ja) 2011-03-03
EA201070780A1 (ru) 2010-12-30
WO2009080698A1 (en) 2009-07-02
US20100305087A1 (en) 2010-12-02
EP2234602A1 (en) 2010-10-06
EP2072042A1 (en) 2009-06-24
CN101903015A (zh) 2010-12-01
AU2008340057A1 (en) 2009-07-02
MX2010006896A (es) 2010-10-05
CA2710125A1 (en) 2009-07-02

Similar Documents

Publication Publication Date Title
BRPI0820381A2 (pt) Formulações farmacêuticas
DK2073795T3 (da) Misbrugssikret lægemiddelformulation
NO20075628L (no) Farmasøytiske formuleringer
BRPI0916877A2 (pt) composição farmacêutica e administração da mesma
BRPI0913379A2 (pt) formulações farmacêuticas sólidas compreendendo bibw 2992
DK2346495T4 (da) Farmaceutisk formulering 514
DK2131813T3 (da) Topiske, farmaceutiske formuleringer
BRPI0807544A2 (pt) Sólido farmacêutico e dose de vacina
CU20080052A7 (es) Formas de presentación farmacéutica sólidas de administración oral con liberación rápida de principio activo
BRPI0908596A2 (pt) formulação e composição farmacêutica de liberação prolongada
EP2130552A4 (en) PHARMACEUTICAL COMPOSITION COMPRISING AN ANTI-GRP78 ANTIBODY AS AN ACTIVE SUBSTANCE
BRPI1009324A2 (pt) compostos e/ou farmaceuticamente aceitáveis dos mesmos, composição farmacêutica e respectivos usos
ITBO20050123A1 (it) Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
DK2381988T3 (da) Medikamentadministrationsanordning
BRPI0915897A2 (pt) compostos derivados triazóis, composições farmacêuticas e combinações dos mesmos e seus usos
BRPI0813384A2 (pt) Suspensões de ingrediente ativo em glicerina
BRPI0812990A2 (pt) Dispositivo de acondicionamento e de administração sublingual de princípios ativos
BRPI0807078A2 (pt) Composto, e, formulação farmacêutica
ATE493119T1 (de) Pharmazeutische zusammensetzung
DK2001297T3 (da) Aktivstofkombinationer insekticide egenskaber
ITMI20050729A1 (it) Nuova formulazione biologicamente attiva
BRPI1009392A2 (pt) "formulação farmacêutica, e, uso de uma quantidade farmaceuticamente eficaz de uma formulação farmacêutica."
BRPI0921654A2 (pt) formulação farmacêutica
BRPI0817833A2 (pt) Composição farmacêutica antimalárica
BRPI1009823A2 (pt) "composição compreendendo um sistema de dispensação de droga, conjunto de uma primeira e uma segunda composição, e, kit."

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.